SOMMF - Ginkgo Bioworks wins DARPA contract worth up to $18M

2023-07-19 08:26:39 ET

Cell platform company Ginkgo Bioworks Holdings ( NYSE: DNA ) announced Wednesday that the Defense Advanced Research Projects Agency (DARPA), an unit operating under the U.S. Department of Defense, awarded it a four-year contract worth up to $18M.

The contract is part of DARPA's Reimagining Protein Manufacturing (RPM) project and relates to the use of Cell-Free Protein Synthesis (CFPS) for rapid and high-yield manufacturing of human therapeutic proteins, Ginkgo ( DNA ) said.

CFPS is a speedier and more flexible method for protein synthesis than traditional manufacturing methods, which can take months to generate the first useful batches of a biological drug.

One of the objectives of DARPA’s RPM project is to develop production methods that comply with Good Manufacturing Practices for their adoption by the pharma industry.

Also on Wednesday, Ginkgo ( DNA ) said that the Japanese chemical company Sumitomo Chemical Co., Ltd. ( OTCPK:SOMMY ) ( OTCPK:SOMMF ) decided to expand the existing biomanufacturing partnership with the company.

More on Ginkgo

• Ginkgo downgraded at William Blair citing concerns on outlook
• Ginkgo Bioworks: Tremendous Potential, But Strong Short Term Headwinds

For further details see: